Dr Doris Beylkin, GE Dharmacon, Colorado, USA

RNAi has long been used for functional genomics screening in cell-based assays.  CRISPR is newer to this application, but showing promise as a complimentary, and possibly more robust mechanism for loss-of function screens.  Whether you are interested in screening a handful of genes, a pathway, or a whole genome, there are several options to consider. In this seminar, we will discuss the various pooled and arrayed options for screens of small gene sets or whole genome collections. In addition to examples of successful assays, we will also present important considerations for your screening workflows and how to choose the best tools for your needs.